Duloxetine Capsules Recalled Over High N-Nitroso Impurity Risk
Towa Pharmaceuticals recalled 3,397 bottles of Duloxetine Delayed-Release Capsules on November 24, 2025. The recall stems from CGMP deviations resulting in N-nitroso-duloxetine levels exceeding FDA limits. Consumers must stop using the product immediately.
About This Product
Duloxetine Delayed-Release Capsules are prescribed for treating depression, anxiety, and certain types of pain. Patients value this medication for its effectiveness in managing chronic conditions.
Why This Is Dangerous
The presence of N-nitroso-duloxetine in the product raises cancer risk concerns, as this impurity exceeds FDA safety limits. Consumers using the affected capsules may face potential long-term health risks.
Industry Context
This recall is not part of a broader industry pattern.
Real-World Impact
Consumers who have purchased this product should stop use immediately to mitigate health risks. They may experience inconvenience in needing to find alternative medications.
Practical Guidance
How to identify if yours is affected
- Check the bottle label for the lot numbers: 240947C or 240962C.
- Verify the expiration date, which should be April 2027.
- Confirm that the product is Duloxetine Delayed-Release Capsules, USP, 60 mg.
Where to find product info
Lot numbers and expiration dates are typically found on the label or the bottom of the bottle.
What timeline to expect
Expect a refund or replacement processing time of approximately 4-6 weeks.
If the manufacturer is unresponsive
- Document all communications with the company regarding the recall.
- Reach out to the FDA if the company does not respond.
How to prevent similar issues
- Always check for recent recalls before using a medication.
- Consult your healthcare provider about alternatives if a medication has been recalled.
- Look for FDA approval and recall history when purchasing medications.
Documentation advice
Keep receipts, communication records, and take photos of the product as evidence.